Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256508844> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W4256508844 endingPage "1007" @default.
- W4256508844 startingPage "1000" @default.
- W4256508844 abstract "PURPOSE: A strong prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor and plasminogen activator inhibitor type 1 (PAI-1) as individual factors is well established in breast cancer. The improvement in clinical risk assessment gained by combining these factors is evaluated here. PATIENTS AND METHODS: uPA and PAI-1 levels were prospectively measured by enzyme-linked immunosorbent assay in tumor tissue extracts of 761 patients with primary breast cancer. RESULTS: In the clinically important subgroup of node-negative patients without adjuvant systemic therapy (n = 269; median follow-up, 60 months), the clinical value of testing both uPA and PAI-1 is demonstrated. The criterion either or both high identifies with high sensitivity the patients at high relapse risk while keeping more than half in the low-risk group. uPA/PAI-1 is the strongest predictor of disease-free survival and overall survival; patients with high uPA/PAI-1 have an increased relapse risk (P < .001; relative risk, 4.8; 95% confidence interval [CI], 2.5 to 9.1), in particular for early relapse. Even within risk groups stratified by established criteria (nodal or menopausal status, tumor size, grade, or steroid hormone receptors), uPA/PAI-1 provides significant risk group discrimination. In the whole collective, the significant interaction between uPA/PAI-1 and adjuvant systemic therapy suggests a benefit from adjuvant therapy in high-risk patients as defined by uPA/PAI-1. CONCLUSION: The clinical relevance of the two tumor-invasion factors uPA and PAI-1 is greatest when they are used in combination. The particular combination of uPA and PAI-1 (both low v either or both high) is superior to either factor alone and supports risk-adapted individualized therapy decisions." @default.
- W4256508844 created "2022-05-12" @default.
- W4256508844 creator A5027231412 @default.
- W4256508844 date "2002-02-15" @default.
- W4256508844 modified "2023-09-23" @default.
- W4256508844 title "Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination" @default.
- W4256508844 doi "https://doi.org/10.1200/jco.20.4.1000" @default.
- W4256508844 hasPublicationYear "2002" @default.
- W4256508844 type Work @default.
- W4256508844 citedByCount "38" @default.
- W4256508844 countsByYear W42565088442012 @default.
- W4256508844 countsByYear W42565088442013 @default.
- W4256508844 countsByYear W42565088442014 @default.
- W4256508844 countsByYear W42565088442015 @default.
- W4256508844 countsByYear W42565088442016 @default.
- W4256508844 crossrefType "journal-article" @default.
- W4256508844 hasAuthorship W4256508844A5027231412 @default.
- W4256508844 hasConcept C121608353 @default.
- W4256508844 hasConcept C126322002 @default.
- W4256508844 hasConcept C143998085 @default.
- W4256508844 hasConcept C2776892390 @default.
- W4256508844 hasConcept C2777863537 @default.
- W4256508844 hasConcept C2777982462 @default.
- W4256508844 hasConcept C2779679481 @default.
- W4256508844 hasConcept C2780275930 @default.
- W4256508844 hasConcept C2780675426 @default.
- W4256508844 hasConcept C530470458 @default.
- W4256508844 hasConcept C71924100 @default.
- W4256508844 hasConceptScore W4256508844C121608353 @default.
- W4256508844 hasConceptScore W4256508844C126322002 @default.
- W4256508844 hasConceptScore W4256508844C143998085 @default.
- W4256508844 hasConceptScore W4256508844C2776892390 @default.
- W4256508844 hasConceptScore W4256508844C2777863537 @default.
- W4256508844 hasConceptScore W4256508844C2777982462 @default.
- W4256508844 hasConceptScore W4256508844C2779679481 @default.
- W4256508844 hasConceptScore W4256508844C2780275930 @default.
- W4256508844 hasConceptScore W4256508844C2780675426 @default.
- W4256508844 hasConceptScore W4256508844C530470458 @default.
- W4256508844 hasConceptScore W4256508844C71924100 @default.
- W4256508844 hasIssue "4" @default.
- W4256508844 hasLocation W42565088441 @default.
- W4256508844 hasOpenAccess W4256508844 @default.
- W4256508844 hasPrimaryLocation W42565088441 @default.
- W4256508844 hasRelatedWork W1989114127 @default.
- W4256508844 hasRelatedWork W2014438829 @default.
- W4256508844 hasRelatedWork W2027833512 @default.
- W4256508844 hasRelatedWork W2085430724 @default.
- W4256508844 hasRelatedWork W2091842478 @default.
- W4256508844 hasRelatedWork W2163676795 @default.
- W4256508844 hasRelatedWork W2177606629 @default.
- W4256508844 hasRelatedWork W4236967495 @default.
- W4256508844 hasRelatedWork W4242306408 @default.
- W4256508844 hasRelatedWork W1809917144 @default.
- W4256508844 hasVolume "20" @default.
- W4256508844 isParatext "false" @default.
- W4256508844 isRetracted "false" @default.
- W4256508844 workType "article" @default.